2-[(4-硝基苯氧基)甲基]环氧乙烷 | 5255-75-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硝基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(4-硝基苯氧基)甲基]环氧乙烷
• 中文别名: 1,2-环氧-3-(对硝基苯氧基)丙烷；1,2-环氧基-3-(4-硝基苯氧基)丙烷
• 英文名称: 1,2-Epoxy-3-(p-nitrophenoxy)propane
• 英文别名: 4-nitrophenyl 2-oxiranylmethyl ether；2-[(4-nitrophenoxy)methyl]oxirane
• CAS: 5255-75-4
• 化学式: C₉H₉NO₄
• 分子量: 195.175
• InChiKey: FPIGOBKNDYAZTP-UHFFFAOYSA-N

物化性质

• 熔点：
  54-55 °C
• 沸点：
  331.83°C (rough estimate)
• 密度：
  1.3544 (rough estimate)
• 稳定性/保质期：

  在常温常压下保持稳定，应避免与不相容材料及强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  67.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  C
• 安全说明：
  S24/25
• 海关编码：
  29109000
• 储存条件：
  密封储存，存放在阴凉、干燥的库房中，并远离腐蚀区域。

SDS

Name:	1 2-Epoxy-3-(4-Nitrophenoxy)Propane Tech. 88% (GC) Material Safety Data Sheet
Synonym:
CAS:	5255-75-4

Section 1 - Chemical Product MSDS Name:1 2-Epoxy-3-(4-Nitrophenoxy)Propane Tech. 88% (GC) Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5255-75-4	1,2-Epoxy-3-(4-Nitrophenoxy)Propane, Y	88	226-057-3

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5255-75-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 65.00 - 67.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NO4
Molecular Weight: 195.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5255-75-4: TZ3650000 LD50/LC50:
CAS# 5255-75-4: Oral, rat: LD50 = >5 gm/kg.
Carcinogenicity:
1,2-Epoxy-3-(4-Nitrophenoxy)Propane, Y Tech. - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5255-75-4: No information available.
Canada
CAS# 5255-75-4 is listed on Canada's DSL List.
CAS# 5255-75-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5255-75-4 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-[(4-硝基苯氧基)甲基]环氧乙烷 在 palladium on activated charcoal 硫酸 、 氢气 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 137.0h， 生成 甲磺司特
  参考文献：
  名称：

  Synthesis and Antiallergic Activity of Dimethyl-2-(phenylcarbamoyl)ethylsulfonium p-Toluenesulfonate Derivatives

  摘要：

  The derivatives of dimethyl-2-(phenylcarbamoyl)ethylsulfonium p-toluenesulfonates were synthesized and evaluated for antiallergic activity. The 2,3-dihydroxyethoxy group was introduced to the phenyl ring from the standpoint of lipophilicity and electronic effects of substituent. The IgE-induced rat passive cutaneous anaphylaxis (PCA) was inhibited by oral administration of several substituted 2-[(4-propoxyphenyl)carbamoyl]ethyldimethylsulfonium p-toluenesulfonate derivatives. Among them (+/-)-2-[4-(3-ethoxy-2-hydroxypropoxy)phenyl]-carbamoyl]ethyldimethylsulfonium p-toluenesulfonate (1a, IPD-1151T) was found to possess considerable activity in the PCA test, and it was launched as Suplatast tosilate in Japan.

  DOI：

  10.1021/jm970285z
• 作为产物：
  描述：

  4-nitrophenol sodium salt 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 96.0h， 生成 2-[(4-硝基苯氧基)甲基]环氧乙烷
  参考文献：
  名称：

  新型N-杂芳烷基取代的1-（芳氧基）-2-丙醇胺及相关丙胺衍生物的合成及Ⅲ类抗心律失常活性。

  摘要：

  描述了一系列新型的1-（芳氧基）-2-丙醇胺和几种相关的脱羟基类似物的合成和生物学评估。制备了化合物4-29，并在分离的犬浦肯野纤维和麻醉的开胸狗中研究了它们的III类电生理活性。这些化合物均未显示出任何I类活性。基于体外数据，讨论了该系列的结构-活性关系。N- [4- [2-羟基-3- [甲基（2-喹啉基甲基）氨基]丙氧基]苯基]甲磺酰胺（12，WAY-123,223）和N- [2-[[甲基[3- [4]鉴定了[[[（甲基磺酰基）氨基]苯氧基]丙基]氨基]甲基] -6-喹啉基]-甲磺酰胺（24，WAY-125,971），并在体外和体内鉴定为有效的和特定的III类抗心律不齐药物。已发现化合物12具有口服生物利用度，可大幅提高心室纤颤阈值（VFT），并且在某些情况下，以5 mg / kg的剂量在麻醉的开胸狗中可恢复室颤的窦性心律（iv ）。合成了12个对映体（即13和14），并在Purkin

  DOI：

  10.1021/jm00115a010

文献信息

• 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
  申请人：AstraZeneca AB

  公开号：US06593326B1

  公开（公告）日：2003-07-15

  A pyrimidine derivative of formula (I): wherein: R1 is an optional substituent as defined within; Rx is selected from halo, hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl, formamido, ureido or carbamoyl or a group of formula (Ib): A—B—C— as defined within; Q1 and Q2 are independently selected from aryl, a 5- or 6-membered monocyclic moiety; and a 9- or 10-membered bicyclic heterocyclic moiety; and one or both of Q1 and Q2 bears on any available carbon atom one substituent of formula (Ia) as defined within; and Q1 and Q2 are optionally further substituted; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式（I）的嘧啶衍生物： 其中：R1是如定义的可选取代基；Rx选自卤素、羟基、硝基、氨基、氰基、巯基、羧基、磺胺基、甲酰胺基、脲基或氨基甲酰基或如定义的式（Ib）的基团：A—B—C—；Q1和Q2独立选自芳基、5-或6-成员单环基；和9-或10-成员双环杂环基；Q1和Q2中的一个或两个在任一可用碳原子上带有如定义的式（Ia）的取代基；Q1和Q2可进一步取代；或其药学上可接受的盐或体内水解酯；可用作抗癌剂；并描述了其制备方法和含有它们的药物组合物。
• New benzoyl piperidine compounds
  申请人：——

  公开号：US20040044033A1

  公开（公告）日：2004-03-04

  Provided herein are racemic or enantiomerically enriched benzoyl piperidine compounds and pharmaceutically useful salts thereof, pharmaceutical compositions comprising an effective amount of racemic or enantiomerically enriched benzoyl piperidine compounds to treat central nervous system diseases and methods of treating central nervous system diseases in a mammal, in particular psychoses and cognition disorders.

  提供本申请中的是外消旋或enantioselectively富集的苯甲酰哌啶化合物及其药用盐,药物组合物包括用于治疗中枢神经系统疾病的racemic或enantioselectively富集的苯甲酰哌啶化合物的有效量,以及治疗哺乳动物中枢神经系统疾病的方法,特别是精神疾病和认知障碍。
• An Unusual (R)-Selective Epoxide Hydrolase with High Activity for Facile Preparation of Enantiopure Glycidyl Ethers
  作者：Jing Zhao、Yan-Yan Chu、Ai-Tao Li、Xin Ju、Xu-Dong Kong、Jiang Pan、Yun Tang、Jian-He Xu

  DOI：10.1002/adsc.201100031

  日期：2011.6

  ortho‐substituted phenyl glycidyl ethers and para‐nitrostyrene oxide. Worthy of note is that the substrate structure remarkably affected the enantioselectivities of the enzyme, as a reversed (S)‐enantiopreference was unexpectedly observed for the ortho‐nitrophenyl glycidyl ether. As a proof‐of‐concept, five enantiopure epoxides (>99% ee) were obtained in high yields, and a gram‐scale preparation of

  从巨大芽孢杆菌ECU1001中克隆了一种新的环氧水解酶（BMEH），该酶具有异常的（R）-对映体选择性和很高的活性。在对位取代的苯基缩水甘油醚和对硝基苯乙烯氧化物的生物拆分中，实现了最高的对映选择性（E > 200）。值得一提的是，底物结构显着影响了酶的对映选择性，因为人们意外地观察到邻硝基硝基苯缩水甘油醚的反向（S）-对映体选择性。作为概念验证，以高收率获得了五种对映纯环氧化合物（> 99％ee），并以克级制备了（S） -邻甲基苯基缩水甘油基醚，然后成功地在几个小时内完成，这表明BMEH为光学活性的环氧化物的高效制备有吸引力的生物催化剂。
• Montmorillonite K10 catalyzed highly regioselective azidolysis of epoxides: A short and efficient synthesis of phenylglycine
  作者：Keshab Ch Ghosh、Isita Banerjee、Surajit Sinha

  DOI：10.1080/00397911.2018.1524494

  日期：2018.11.17

  Abstract A series of β‐hydroxyazides were effectively synthesized from the regioselective ring opening of epoxides by sodium azide using montmorillonite K10 as a novel heterogeneous catalyst in aqueous acetonitrile in good to excellent yields. The utility of this method has been demonstrated by achieving a short synthesis of phenylglycine in 33.5% overall yield. Graphical Abstract

  摘要 以蒙脱石 K10 作为新型多相催化剂，在乙腈水溶液中，通过叠氮化钠对环氧化物的区域选择性开环，有效合成了一系列 β-羟基叠氮化物，收率良好。通过以 33.5% 的总收率实现苯基甘氨酸的短时间合成，证明了该方法的实用性。图形概要
• Bispidine antiarrhythmic compounds
  申请人：AstraZeneca AB

  公开号：US06291475B1

  公开（公告）日：2001-09-18

  There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

  提供了一个式I的化合物， 其中R1、R2、R9、R10、R11、R12、X、A和B的含义如描述中所给，这些化合物在心律失常的预防和治疗中特别有用，尤其是房颤和室颤。